9q33.3, A Stress-Related Chromosome Region, Contributes to Reducing Lung Squamous Cell Carcinoma Risk  by Xiao, Qin et al.
1041Journal of Thoracic Oncology ®  •  Volume 9, Number 7, July 2014
Background: Human chromosome 9q33.3 is one of the most impor-
tant loci for pathophysiological stresses with complex genetic traits. 
We hypothesized that the common single-nucleotide polymorphisms 
on this region may affect non–small-cell lung cancer risk.
Methods: We genotyped 43 single-nucleotide polymorphisms that 
span 13 genes on 9q33.3 in two independent cohorts: the discov-
ery study including 485 cases and 532 controls (North China) and 
the replicative study including 1063 cases and 1247 controls (South 
China). Both of the discovery cohort and the replicative cohort were 
included in the combined study.
Results: In the discovery study, we identified a potential protective locus 
rs10118570 in mitogen-activated protein kinase associated protein 1 with 
a lower population attributable risk under logistical regression adjusted 
by age, gender, smoking, and drinking status (adjusted odds ratio [OR] 
0.26, 95% confidence interval [CI] 0.10–0.71, p = 1.138 × 10–3 for 
genotype GG in lung squamous cell carcinoma). This protective qual-
ity increased in a dose-dependent manner as genotype GG decreased 
(p
trend
 = 9.675 × 10–4). Replicative and combined studies showed consis-
tent association for this genotype (replicative: adjusted OR 0.36, 95% CI 
0.20–0.66, p = 6.109 × 10–4, p
trend
 = 7.386 × 10–4; combined: adjusted OR 
0.33, 95% CI 0.18–0.55, p = 1.259 × 10–6, p
trend
 = 7.725 × 10–6).
Conclusion: We concluded that mitogen-activated protein kinase 
associated protein 1 rs10118570 may be an important protective fac-
tor for developing better management strategies in lung squamous 
cell carcinoma.
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(J Thorac Oncol. 2014;9: 1041–1047)
Lung cancer is now one of the commonest malignancies affect-ing both men and women in the world. There are over one mil-
lion deaths worldwide per year because of lung cancer, making it 
truly an epidemic. Non–small-cell lung cancer (NSCLC) accounts 
for approximately 80% of all cases of lung cancer.1 Many studies 
have shown that NSCLC has been associated with 19q13, 17p13, 
15q25, 13q14, 10q24, 9p21, 8p21-23, 7p, and 3p.2–4 It is clear 
that NSCLC display a remarkable extent of genetic heterogene-
ity, both between and within individual patients.
According to comparative genomic analysis, human 
9q33.3 and 45 vertebrate homologous sequences are evolution-
arily conserved among diverse species (Supplementary Figure 
1, SDC 1, http://links.lww.com/JTO/A593). Individual dis-
plays an increased/decreased susceptibility to certain disease, 
perhaps owing to genetic stress. The 9q33.3 is also one of the 
most important loci for stress-related syndromes and intricate 
function (Supplementary Table 1, SDC 1, http://links.lww.com/
JTO/A593). Recent studies (including our laboratory’s work) 
reported the variants of 78 kDa glucose-regulated protein 
(GRP78) gene on 9q33.3 to be involved in stress-related syn-
dromes, e.g., chronic hepatitis B virus (HBV) infection risk,5 
liver cancer risk/prognosis,6 gastric and colorectal cancer, and 
NSCLC prognosis.7–9 Although our previous study did not vali-
date a predisposition of GRP78 to NSCLC risk,10 we would pre-
sume 9q33.3 locus has potential association with this disease.
MATERIALS AND METHODS
Participants
In the discovery study, 489 unrelated diagnosed/hospital-
ized NSCLC patients and 532 healthy controls with medical 
examination were recruited from Zibo Center Hospital in North 
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China from November 2003 to December 2007. Then, 1063 
NSCLC patients and 1247 healthy controls were recruited from 
the Affiliated Cancer Hospital of Guangzhou Medical College 
in Guangzhou in South China between September 2001 and 
December 2007 as the replicative cohort. They all were Han 
Chinese origin population. Both of the discovery cohort and the 
replicative cohort were included in the combined study.
Patients were first checked by a crowd of experts con-
sisting of oncologists, image diagnosticians, pathologists, 
and surgeons. All patients were diagnosed as NSCLC by 
computed tomography (CT), magnetic resonance imaging, 
and cytologic or pathologic examination. The clinical data 
of patients including age at diagnosis, gender, smoking and 
drinking habit, clinical chemistry and blood data, HBV, anti-
hepatitits C virus (HCV), clinical stages, and tumor histologi-
cal styles were systematically recorded at entry. Smoking was 
estimated by valuing subjects who have smoked more than 
1000 cigarettes over a lifetime were defined as smokers. If a 
participant consumed mean 59 g of alcohol per week it means 
that he or she is an alcohol drinker. We only selected that the 
clinical records is complete, and the patients in our study were 
unconsecutive. Thus, the cases represented an unconsecutive 
series. Tumor stage at the time of diagnosis was determined 
according to the clinical tumor-nodes-metastasis classification 
(cTNM) of the International Union Against Cancer (UICC) 
using hospital records. There were no age, gender, stage, or 
histology restrictions; however, patients with relapsing cancer 
or metastatic carcinoma from other organs were excluded.
For controls, age, gender, smoking, and drinking habits 
and clinical blood data were recorded too. The control series 
were volunteers after physical checkup. All participants were 
exclude tuberculosis, HBV, and HCV infection. The main 
features of the subjects included are summarized in Table 1. 
The study protocol was approved by The Ethics Committee 
of Guangdong Medical College and in accordance with the 
Declaration of Helsinki of the World Medical Association. In 
addition, written informed consent was obtained from partici-
pants or their kins.
TABLE 1.  Baseline Characteristics of the Cohorts
Characteristics
Discovery Cohort Replicative Cohort Combined Cohort
Cases Controls p Cases Controls p Cases Controls P
No. of subjects 485 532 1063 1247 1548 1779
Origin NC, Han NC, Han SC, Han SC, Han both both
Age (years) Mean ± SD 62.5 ± 15.7 33.0 ± 9.2 <0.001a 58.5 ± 18.2 35.6 ± 12.3 <0.001a 60.1 ± 17.8 34.8 ± 11.1 <0.001a
Female (%) 115 ( 23.71) 173 (32.52) 0.002b 341 (32.08) 543 (43.54) <0.001b 456 (29.46) 716 (40.25) <0.001b
Smoking (n, %) 207 (42.68) 115 (21.62) <0.001b 487 (45.81) 357 (28.63) <0.001b 694 (44.83) 472 (26.53) <0.001b
  Missing 8 (1.65) 17 (3.20) 29 (2.73) 40 (3.21) 37 (2.39) 57 (3.20)
Drinking (n, %) 141 (29.07) 147 (27.63) 0.764b 275 (25.87) 246 (19.73) <0.001b 416 (26.87) 393 (22.09) 0.002b
  Missing 12 (2.47) 24 (4.51) 55 (5.17) 69 (5.53) 67 (4.33) 93 (5.23)
Hemoglobin level g/dL, mean (± SD) 9.8 ± 3.4 12.3 ± 2.4 <0.001a 10.4 ± 3.7 12.5 ± 2.5 <0.001a 10.2 ± 3.7 12.5 ± 2.4 <0.001a
Corpuscular volume, mean (fL, ± SD) 91.6 ± 8.5 88.7 ± 8.5 <0.001a 90.4 ± 10.0 89.5 ± 8.1 0.003a 90.8 ± 9.6 89.1 ± 8.3 <0.001a
White blood cells, mean (×109/l, ± SD) 7.3 ± 3.0 7.3 ± 2.3 0.282a 7.1 ± 2.9 7.5 ± 2.4 <0.001a 7.2 ± 3.0 7.4 ± 2.4 <0.001a
Anti-tuberculosis (n, %) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
HBV (HBsAg+, n, %) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Anti-HCV (n, %) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00)
Liver function (mean ± SD)
  T-Bil (μmol/l) 12.7 ± 7.5 11.8 ± 6.9 0.001a 12.5 ± 7.9 11.2 ± 7.2 <0.001a 12.6 ± 7.7 11.6 ± 7.2 <0.001a
  ALB (g/l) 36.1 ± 5.2 42.9 ± 6.1 <0.001a 35.3 ± 5.8 42.8 ± 6.4 <0.001a 35.6 ± 6.2 42.9 ± 6.3 <0.001a
  ALT (IU/l) 69 ± 32.6 21.8 ± 13.7 <0.001a 94 ± 64.7 23.3 ± 8.5 <0.001a 88 ± 58.1 22.6 ± 13.4 <0.001a
Stage (n, %)
  I 69 (14.23) 155 (14.58) 224 (14.47)
  II 95 (19.59) 205 (19.29) 300 (19.38)
  IIIB 183 (37.73) 314 (29.54) 497 (32.11)
  IV 138 (28.45) 389 (36.59) 527 (34.04)
Histology (n, %)
  Squamous cell 247 (50.93) 471 (44.31) 718 (46.38)
  Adenocarcinoma 132 (27.22) 337 (31.70) 469 (30.30)
  BAC features 53 (10.93) 138 (12.98) 191 (12.34)
  Large cell 25 (5.15) 61 (5.74) 86 (5.56)
  NSCLC NOS 28 (5.77)   56 (5.27)   84 (5.43)   
BAC, bronchioloalveolar carcinoma; NSCLC, non–small-cell lung cancer; NOS, not otherwise specified. NC, North China; SC, South China.
aKruskal-Wallis test for continuous variables.
bχ2 test for categorical variables.
1043Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 7, July 2014 9q33.3 Reducing Lung Squamous Cell Carcinoma Risk
Single-Nucleotide Polymorphism 
Selection and Genotyping
Forty-three single-nucleotide polymorphisms (SNPs) 
on 13 genes were selected randomly from the National 
Center for Biotechnology Information SNP Database. The 
selected SNPs were high heterozygosity with minor allele 
frequencies greater than 10% at approximate intervals of 
64 kb across the euchromatic regions of chromosome 9q33.3. 
Blood samples were collected from all study subjects at the 
time of recruitment. Then, the genomic DNA was prepared 
from peripheral leukocytes using QIAGEN QIAamp DNA 
Mini Blood Kit (Hilden, Germany). In reference to the Homo 
sapiens chromosome 9q33.3 sequence (Genbank Accession 
No. NT_008470.18), 37 sets of polymerase chain reaction 
(PCR) primers and 39 sequencing primers were designed for 
43 SNP screening. The primers for PCR and resequencing 
are listed in Supplementary Table 2 (SDC 1, http://links.lww.
com/JTO/A593).
Statistical Analysis
The detailed information is available at Supporting 
Information.
RESULTS
All SNPs conformed to the Hardy-Weinberg equilib-
rium in the control cohorts (data not shown). In the discovery 
cohort, the SNPs were determined by resequencing of PCR 
products. The 9q33.3 plot displaying the resulting p values 
with respect to genomic position was shown. rs10118570 
which located within mitogen-activated protein kinase asso-
ciated protein 1 (MAPKAP1) achieved marginal significance 
after Bonferroni correction in the discovery cohort (unad-
justed, p = 3.750 × 10–3; Fig. 1A). This SNP showed lower 
population attributable risk (1.157 × 10–3) under logistical 
regression adjusted by age, gender, smoking, and drinking 
status (Table 2). It remained marginally significant after 105 
permutation tests (p
empirical
 = 0.0445).
Q-Q plots were used to compare the observed χ2 values 
with the distribution expected under the null hypothesis, where 
deviation from expectation was observed at higher value of 
approximately 5.2 (Fig. 1B). After removing rs10118570, we 
did not observe an excess of χ2 value compared with the dis-
tribution expected (Fig. 1C), suggesting that only rs10118570 
is a potential locus that deserve merit additional investigation.
We found both observed and predicted heterozygosities 
of rs10118570 in cases are lower than that in controls. Because 
it did achieve a Bonferroni correction level with logisti-
cal regression in comparing homozygous variant (GG) with 
homozygous ancestral type (AA; RR
HOM
 = 0.34, 95% confi-
dence interval [CI] 0.17–0.66, p = 9.945 × 10–4; Supplementary 
Figure 2, SDC 1, http://links.lww.com/JTO/A593), genotype 
GG perhaps plays a causative role. Indeed, rs10118570 GG 
showed marginal significance of protective role with NSCLC 
in the discovery cohort (adjusted odds ratio [OR] 0.37, 95% 
CI 0.20–0.67, p = 1.195 × 10–3; Table 3). Especially, the above 
SNP also showed a strong trend for association with reduc-
ing risk of NSCLC (p
trend
 = 8.510 × 10–4; Table 3 and Figure 2, 
SDC 1, http://links.lww.com/JTO/A593).
Patterns of LD in the 43 SNPs were illustrated by their 
D’ and r2 values. Three inheritance blocks were identified 
(Fig. 1D). The results of the haplotype-based case-control 
study between the NSCLC and control groups are shown in 
Supplementary Table 3 (SDC 1, http://links.lww.com/JTO/
A593). The overall distribution of haplotypes did not reveal 
a statistically significant difference between the NSCLC 
patients and control subjects by logistical regression analysis. 
The permutation data of the blocks also did not achieve a sig-
nificant association.
A decreased frequencies of diplotype Gd-CT-CC-AG 
(adjusted OR 0.69, 95% CI 0.51–0.92, p = 0.009) and an 
increased frequencies of diplotype dd-CT-CC-GG (adjusted OR 
1.37, 95% CI 1.06–2.38, p = 0.011) in block 2 were observed in 
NSCLC patients compared with healthy controls. However, the 
significance was lost after Bonferroni correction (Supplementary 
Figure 3, SDC 1, http://links.lww.com/JTO/A593).
We also replicated the disease association with 
rs10118570 found in the discovery cohort in an indepen-
dent cohorts from Guangzhou (cases n = 1063 and controls 
n = 1247; Supplementary Table 1, SDC 1, http://links.lww.
com/JTO/A593). Replicative results showed consistent asso-
ciation for rs10118570 genotype GG (adjusted OR 0.45, 95% 
CI 0.29–0.69, p = 1.681 × 10–4, p
trend
 = 8.027 × 10–4; Table 3). 
Lastly, the combined study including the discovery and rep-
licative cohorts was carried out. The combined results also 
showed a positive association for rs10118570 genotype GG 
by Bonferroni correction in multiple testing (adjusted OR 
0.43, 95% CI 0.30–0.62, p = 1.352 × 10–6, p
trend
 = 8.811 × 10–6; 
Table 3).
We analyze the data according to the different histol-
ogy groups (mainly squamous cell carcinoma and adenocarci-
noma). In the discovery cohort, rs10118570 GG also showed 
marginal significance of protective role and a strong trend 
for association with sqaumous cell carcinoma (adjusted OR 
0.26, 95% CI 0.10–0.71, p = 1.138 × 10–3, p
trend
 = 9.675 × 10–4; 
Table 4). Replicative and combined studies showed consistent 
association for this genotype (replicative: adjusted OR 0.36, 
95% CI 0.20–0.66, p = 6.109 × 10–4, p
trend
 = 7.386 × 10–4; com-
bined: adjusted OR 0.33, 95% CI 0.18–0.55, p = 1.259 × 10–6, 
p
trend
 = 7.725 × 10–6). According to the p values for trend, this 
protective quality increased in a dose-dependent manner as 
genotype GG decreased. Nevertheless, we could find no evi-
dence for an association between this SNP and adenocarci-
noma in the Chinese population (Supplementary Table 4, 
SDC 1, http://links.lww.com/JTO/A593).
DISCUSSION
In the present study, we investigated the role of 9q33.3 
polymorphisms in the risk of NSCLC susceptibility in Han 
Chinese. Our results revealed the MAPKAP1 gene was asso-
ciated with squamous cell carcinoma risk. MAPKAP1 also 
called stress activated protein kinase-interacting protein 1 
(SIN1), which is highly conserved in vertebrates. It had been 
poorly studied until several years ago, although it is currently 
absorbing considerable attention. Many studies certified that 
the stress induced by tumorigenesis primings genomic insta-
bility, which is a patulous hallmark in tumor development.11,12 
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Incremental instability induced by stress in cancer cells was 
speculated to be the result of Darwinian selection of sub-
clones.13 MAPKAP1 could be involved in responses within the 
endoplasmic reticulum to stress in mammalian cells and pro-
vide a platform for organizing responses to a variety of exter-
nal cell stressors. Therefore, we speculated that MAPKAP1 
might play an important role in tumorigenesis and might be 
owing to, at least partially, genetic instability induced by car-
cinogenesis involved in regulating signal transductions.
Recent study showed that MAPKAP1 (SIN1) was 
capable of promoting invasion and metastasis of hepatocel-
lular carcinoma by facilitating epithelial-mesenchymal tran-
sition.15 Because histanoxia indicates a trait of solid tumors, 
the specific microenvironment may allow signals that evoke a 
protracted expression in angiogenic gene during carcinogen-
esis. Actually, by receiving input stress signals from various 
pathways, MAPKAP1 could promote procedures that either 
protect cells from stress-induced apoptosis or accelerate pro-
grammed cell death, including the junction with a functional 
RNA binding protein PCBP2 controlling of RNA stability and 
translation, as scaffold molecules assembling phosphorylation 
complex, and maintaining mammalian target of rapamycin 
complex 2 (mTORC2) kinase activity.14
MAPKAP1 phosphorylation could injure mTORC2 
complex compomers integrity and inhibit downstream Akt 
signaling, further suppresses tumorigenesis.16 Moreover, 
FIGURE 1.  The case-control associa-
tion, Q-Q plot and linkage disequi-
librium in the discovery study. A, 
the results (−log10 of p values) of the 
association of single-nucleotide poly-
morphisms (SNPs) with S. japonicum 
infection on 9q33.3. (B) Q-Q plot 
for the test statistics of observed χ2 
values against expected χ2 values. 
(C) Q-Q plot for the test statistics of 
observed χ2 values against expected 
χ2 values removing the rs10118570. 
(D) Linkage disequilibrium map-
ping. The block 1 encompasses the 
promoter of PSMB7 to the seventh 
intron of GPR144 and is 36 kb; block 
2 includes the 5′ UTR and promoter 
of GRP78 and is only 236bp; block 3 
extends near 16.5kb from FAM125B 
promoter to its first intron. The blue 
ellipse indicates the potential SNP 
that not belongs to any block.
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TABLE 2.   Association of Candidate Gene Single-Nucleotide Polymorphisms on Chromosome 9q33.3 with Non–Small-Cell 
Lung Cancer in the Discovery Study
rs ID
Chr.
Locationa Genes Types A>Bb Cc
Allele ratios: Frequency:
PARf
Permutation
Analysisg
Cases, Controlsd Cases, Controlse X2 P
empirical
rs10986309 127067131 NEK6 Intron G>A A 229:741, 242:822 0.236, 0.227 0.617 0.213 1
rs944333 127087002 NEK6 Intron A>G G 417:553, 444:620 0.430, 0.417 0.56 0.33 1
rs4574 127177161 PSMB7 V39A T>C C 236:734, 235:829 0.243, 0.221 0.217 1.435 0.9998
rs12343206 127184067 PSMB7 Promoter A>G A 693:277, 744:320 0.714, 0.699 0.485 0.564 1
rs10733669 127220133 GPR144 Intron G>A A 640:330, 696:368 0.660, 0.654 0.811 0.072 1
rs4838186 127238332 GPR144 Intron C>T T 731:239, 800:264 0.754, 0.752 0.852 0.008 1
rs4838208 127528035 NR6A1 Intron A>C C 647:323, 708:356 0.667, 0.665 0.906 0.006 1
rs4838209 127528842 NR6A1 Intron T>C T 663:307, 720:344 0.684, 0.677 0.72 0.108 1
rs634710 127661645 GOLGA1 T425M T>C T 708:262, 756:308 0.730, 0.711 0.383 0.944 1
rs7031479 127686126 GOLGA1 Intron T>C T 644:326, 700:364 0.664, 0.658 0.754 0.082 1
rs7040520 127711321 GOLGA1 Promoter A>G A 708:262, 756:308 0.730, 0.711 0.385 0.944 1
rs10760394 127962533 RABEPK Promoter G>A A 297:673, 318:746 0.306, 0.299 0.729 0.129 1
rs420423 127969785 RABEPK Intron (boundary) T>C T 729:241, 783:281 0.752, 0.736 0.404 0.651 1
rs359591 127979491 RABEPK Intron A>G G 313:657, 342:722 0.323, 0.321 0.93 0.004 1
rs599063 127996046 GRP78 Downstream A>G G 242:728, 222:842 0.249, 0.209 0.016 4.806 0.6474
rs418496 127996479 GRP78 Downstream G>A A 217:753, 207:857 0.224, 0.195 0.057 2.615 0.9762
rs12009 127997303 GRP78 3′ UTR T>C T 603:367, 652:412 0.622, 0.613 0.713 0.169 1
rs1140763 127997592 GRP78 3′ UTR T>C T 540:430, 566:498 0.557, 0.532 0.293 1.252 1
rs16927997 127998397 GRP78 3′ UTR T>C C 85:885, 93:971 0.088, 0.087 0.934 0 1
rs430397 128001119 GRP78 Intron (boundary) G>A A 204:766, 212:852 0.210, 0.199 0.522 0.382 1
rs11355458 128003789 GRP78 5′ UTR hd>G G 733:237, 780:284 0.756, 0.733 0.298 1.359 0.9999
rs17840761 128003979 GRP78 Promoter C>T T 606:364, 627:437 0.625, 0.589 0.136 2.672 0.9734
rs17840762 128003987 GRP78 Promoter C>T T 233:737, 221:843 0.240, 0.208 0.081 3.091 0.9396
rs391957 128004024 GRP78 Promoter G>A A 733:237, 780:284 0.756, 0.733 0.286 1.359 0.9999
rs372225 128024049 GAPVD1 Promoter C>T C 525:445, 562:502 0.541, 0.528 0.574 0.347 1
rs10819043 128037245 GAPVD1 Intron T>C C 391:579, 407:657 0.403, 0.383 0.361 0.901 1
rs359587 128058377 GAPVD1 Intron T>A T 534:436, 572:492 0.551, 0.538 0.483 0.341 1
rs12202 128200299 MAPKAP1 3′ UTR G>C C 232:738, 230:834 0.239, 0.216 0.242 1.53 0.9996
rs7046471 128250409 MAPKAP1 Intron T>C T 658:312, 704:360 0.678, 0.662 0.498 0.639 1
rs10986849 128469683 MAPKAP1 Promoter A>G A 213:757, 230:834 0.220, 0.216 0.817 0.035 1
rs4837022 128475379 MAPKAP1 Promoter C>T T 203:767, 211:853 0.209, 0.198 0.573 0.377 1
rs10118570 128476464 MAPKAP1 Promoter A>G G 792:178, 813:251 0.816, 0.764 1.157 × 10–3 10.681 0.0445
rs10760403 128608495 PBX3 Intron T>G T 180:790, 196:868 0.186, 0.184 0.906 0.006 1
rs1477147 128736511 PBX3 Downstream C>G G 242:728, 232:832 0.249, 0.218 0.085 2.806 0.9649
rs10819146 129084932 FAM125B Promoter G>C C 392:578, 408:656 0.404, 0.383 0.383 0.908 1
rs531599 129101389 FAM125B Intron G>C C 233:737, 224:840 0.240, 0.211 0.118 2.566 0.978
rs10760443 129395346 LMX1B Intron T>C C 666:304, 728:336 0.687, 0.684 0.882 0.013 1
rs12336217 129399870 LMX1B Intron A>G G 344:626, 319:745 0.355, 0.300 0.013 6.942 0.2876
rs3850585 129436272 LMX1B Intron C>T T 390:580, 400:664 0.402, 0.376 0.251 1.458 0.9998
rs2454217 129679933 RALGPS1 Intron A>G G 163:807, 144:920 0.168, 0.135 0.034 4.235 0.7619
rs487914 129698639 RALGPS1 Intron A>C C 168:802, 146:918 0.173, 0.137 0.02 5.031 0.6114
rs488039 129698676 RALGPS1 Intron A>G G 155:815, 151:913 0.160, 0.142 0.297 1.269 1
rs1890546 129952141 RALGPS1 Intron T>C C 256:714, 259:805 0.264, 0.243 0.334 1.127 1
aPositions according to genomic contig NT_008470.18 (Entrez Nucleotide) in National Center for Biotechnology Information Genome Build 36.2.
bThe major allele is listed first, then the minor allele.
cPotential causal allele.
dNumber of alleles were compared in cases versus controls: allele (1):allele (2) cases, allele (1):allele (2) controls.
eFrequency of the association allele.
fPAR, population attributable risk. Calculated in logistical regression models with adjustment for age, gender, smoking, and drinking status. Population attributable risk < 1.163 × 10–3 
means significant value by Bonferroni correction based on the total number of markers genotyped.
gEmpirical p value based on 105 permutations of case-control status using the max(T) procedure. p < 0.05 means significant value.
hd, the delete base.
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hyperactivated mTORC2 in glioma could enhance tumor cell 
proliferation and invasive potency owing to incremental com-
plex formation as a result of the overexpression of RPTOR 
independent companion of mTOR, complex 2 (RICTOR).17 
They also suggesting that a mutations in the mTORC1-S6K-
Sin1 signaling axis might cause aberrant hyperactivation of 
the mTORC2-Akt pathway, which facilitates tumorigenesis.
In summary, we firstly identified a polymorphism on 
9q33.3, a stress-related and evolutionally conservative chro-
mosome region that was highly associated with reducing 
squamous cell carcinoma risk in two independent cohorts 
from Chinese descent. Understanding the genetic complexity 
of lung cancer and using this information would develop bet-
ter management strategies. Additional Supporting Information 
may follow this manuscript.
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